Skip to main content
Erschienen in: Drugs 5/2009

01.03.2009 | Review Article

The Role of Antipsychotics in the Management of Behavioural Symptoms in Children and Adolescents with Autism

verfasst von: Prof. Richard P. Malone, Ayesha Waheed

Erschienen in: Drugs | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Autistic disorder or autism is a serious childhood-onset disorder that affects all areas of development, particularly in the areas of language, communication and reciprocal social interaction. Patients with autistic disorder typically demonstrate repetitiveness and a restricted repertoire of behaviour. Additionally, they also have a number of disruptive symptoms that may be reduced by drug treatment, including severe tantrums, hyperactivity and lability.
Antipsychotic drugs are the agents that are the most critically studied as treatments for reducing symptoms. Both first- and second-generation antipsychotics have shown safety and efficacy in short- and long-term studies in autism. The most studied antipsychotic drugs include haloperidol and risperidone, although studies of other antipsychotic drugs are underway. Safety concerns associated with treatment include the risk of drug-related dyskinesias, which is greater with the first-generation drugs, and the risk of weight gain and associated metabolic problems (i.e. increases in glucose and lipids), which is greater with second-generation agents. Prescription of antipsychotic drugs requires careful monitoring because of these safety risks and the likelihood of long-term use. Drug administration should be initiated at low dosages and subsequent dosage changes should be based on tolerability and clinical response.
Literatur
1.
Zurück zum Zitat American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000
2.
Zurück zum Zitat Newschaffer CJ, Croen LA, Daniels J, et al. The epidemiology of autism spectrum disorders. Annu Rev Public Health 2006; 28: 21.1-21.24 Newschaffer CJ, Croen LA, Daniels J, et al. The epidemiology of autism spectrum disorders. Annu Rev Public Health 2006; 28: 21.1-21.24
3.
Zurück zum Zitat Center for Disease Control. Prevlence of autism spectrum disorders: Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2002. MMWR (Surveillance Summaries) 2007; 56 (SS-1): 12–28 Center for Disease Control. Prevlence of autism spectrum disorders: Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2002. MMWR (Surveillance Summaries) 2007; 56 (SS-1): 12–28
4.
Zurück zum Zitat Malone RP, Gratz S, Delaney MA, et al. Recent advances in drug treatments in children and adolescents with pervasive developmental disorder. CNS Drugs 2005; 19(11): 923–34PubMedCrossRef Malone RP, Gratz S, Delaney MA, et al. Recent advances in drug treatments in children and adolescents with pervasive developmental disorder. CNS Drugs 2005; 19(11): 923–34PubMedCrossRef
5.
Zurück zum Zitat Fedorowicz VJ, Fombonne E. Metabolic side effects of atypical antipsychotics in children: a literature review. J Psychopharmacol 2005; 19(5): 533–50PubMedCrossRef Fedorowicz VJ, Fombonne E. Metabolic side effects of atypical antipsychotics in children: a literature review. J Psychopharmacol 2005; 19(5): 533–50PubMedCrossRef
6.
Zurück zum Zitat Campbell M, Anderson LT, Meier M, et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Adolesc Psychiatry 1978; 17(4): 640–55CrossRef Campbell M, Anderson LT, Meier M, et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Adolesc Psychiatry 1978; 17(4): 640–55CrossRef
7.
Zurück zum Zitat Cohen IL, Campbell M, Posner D, et al. Behavioral effects of haloperidol in young autistic children. J Am Acad Child Adolesc Psychiatry 1980; 19(4): 665–77CrossRef Cohen IL, Campbell M, Posner D, et al. Behavioral effects of haloperidol in young autistic children. J Am Acad Child Adolesc Psychiatry 1980; 19(4): 665–77CrossRef
8.
Zurück zum Zitat Anderson LT, Campbell M, Grega DM, et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984; 141(10): 1195–202PubMed Anderson LT, Campbell M, Grega DM, et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984; 141(10): 1195–202PubMed
9.
Zurück zum Zitat Anderson LT, Campbell M, Adams P, et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 1989; 19(2): 227–39PubMedCrossRef Anderson LT, Campbell M, Adams P, et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 1989; 19(2): 227–39PubMedCrossRef
10.
Zurück zum Zitat Perry R, Campbell M, Adams P, et al. Long term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 1989; 28(1): 87–92PubMedCrossRef Perry R, Campbell M, Adams P, et al. Long term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 1989; 28(1): 87–92PubMedCrossRef
11.
Zurück zum Zitat Faretra G, Dooher L, Dowling J. Comparison of haloperidol and fluphenazine in disturbed children. Am J Psychiatry 1970; 126(11): 1670–3PubMed Faretra G, Dooher L, Dowling J. Comparison of haloperidol and fluphenazine in disturbed children. Am J Psychiatry 1970; 126(11): 1670–3PubMed
12.
Zurück zum Zitat Naruse H, Nagahata M, Nakane Y, et al. A multi-center double blind trial of pimozide, haloperidol, and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatr 1982; 48(4): 173–84PubMed Naruse H, Nagahata M, Nakane Y, et al. A multi-center double blind trial of pimozide, haloperidol, and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatr 1982; 48(4): 173–84PubMed
13.
Zurück zum Zitat Remington G, Sloman L, Konstantareas M, et al. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 2001; 21(4): 440–44PubMedCrossRef Remington G, Sloman L, Konstantareas M, et al. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 2001; 21(4): 440–44PubMedCrossRef
14.
Zurück zum Zitat Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114: 634–41CrossRef Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114: 634–41CrossRef
15.
Zurück zum Zitat Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006; 16(5): 541–8PubMedCrossRef Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006; 16(5): 541–8PubMedCrossRef
16.
Zurück zum Zitat Ernst M, Magee HJ, Gonzalez NM, et al. Pimozide in autistic children. Psychopharmacol Bull 1992; 28(2): 187–91PubMed Ernst M, Magee HJ, Gonzalez NM, et al. Pimozide in autistic children. Psychopharmacol Bull 1992; 28(2): 187–91PubMed
17.
Zurück zum Zitat Tarjan G, Lowery VE, Wright SW. Use of chlorpromazine in two hundred seventy eight mentally deficient patients. AMA J Dis Child 1957; 94(3): 294–300PubMed Tarjan G, Lowery VE, Wright SW. Use of chlorpromazine in two hundred seventy eight mentally deficient patients. AMA J Dis Child 1957; 94(3): 294–300PubMed
18.
Zurück zum Zitat Campbell M, Armenteros JL, Malone RP, et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997; 36(6): 835–43PubMedCrossRef Campbell M, Armenteros JL, Malone RP, et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997; 36(6): 835–43PubMedCrossRef
19.
Zurück zum Zitat Fish B, Shapiro T, Campbell M. Long term prognosis and the response of schizophrenic children to drug therapy: a controlled study of trifluoperazine. Am J Psychiatry 1966; 123: 32–9PubMed Fish B, Shapiro T, Campbell M. Long term prognosis and the response of schizophrenic children to drug therapy: a controlled study of trifluoperazine. Am J Psychiatry 1966; 123: 32–9PubMed
20.
Zurück zum Zitat Research Units on Pediatric Psychopharmacology Autism Network (RUPPAN). Risperidone in children with autism for serious behavioral problems. N Engl J Med 2002; 347: 314–21CrossRef Research Units on Pediatric Psychopharmacology Autism Network (RUPPAN). Risperidone in children with autism for serious behavioral problems. N Engl J Med 2002; 347: 314–21CrossRef
21.
Zurück zum Zitat Research Units on Pediatric Psychopharmacology Autism Network (RUPPAN). Risperidone treatment of autistic disorder: longer term benefits and blinded discontinuation after six months. Am J Psychiatry 2005; 162(7): 1361–9CrossRef Research Units on Pediatric Psychopharmacology Autism Network (RUPPAN). Risperidone treatment of autistic disorder: longer term benefits and blinded discontinuation after six months. Am J Psychiatry 2005; 162(7): 1361–9CrossRef
22.
Zurück zum Zitat Troost PW, Lahuis BE, Steenhuis M, et al. Long term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adol Psychiatry 2005; 44(11): 1137–44CrossRef Troost PW, Lahuis BE, Steenhuis M, et al. Long term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adol Psychiatry 2005; 44(11): 1137–44CrossRef
23.
Zurück zum Zitat Malone RP, Maislin G, Choudhury MS, et al. Risperidone treatment in children and adolescents with autism: short and long term safety and effectiveness. J Am Acad Child Adol Psychiatry 2002; 41(2): 140–7CrossRef Malone RP, Maislin G, Choudhury MS, et al. Risperidone treatment in children and adolescents with autism: short and long term safety and effectiveness. J Am Acad Child Adol Psychiatry 2002; 41(2): 140–7CrossRef
24.
Zurück zum Zitat Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adol Psychiatry 2001; 40(8): 887–94CrossRef Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adol Psychiatry 2001; 40(8): 887–94CrossRef
25.
Zurück zum Zitat National Institute of Mental Health (NIMH). Long-term olanzapine treatment in children with autism [Clinical-Trials.gov identifier NCT00183404]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Mar 25] National Institute of Mental Health (NIMH). Long-term olanzapine treatment in children with autism [Clinical-Trials.gov identifier NCT00183404]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2009 Mar 25]
26.
Zurück zum Zitat Reilly T, Kirk M. Atypical antipsychotics and newer anti-depressants. Emerg Med Clin North Am 2007; 25(2): 477–97PubMedCrossRef Reilly T, Kirk M. Atypical antipsychotics and newer anti-depressants. Emerg Med Clin North Am 2007; 25(2): 477–97PubMedCrossRef
27.
Zurück zum Zitat Ziprasidone: a novel psychotropic with unique properties. Expert Rev Neurother 2004; 4(2): 179-86 Ziprasidone: a novel psychotropic with unique properties. Expert Rev Neurother 2004; 4(2): 179-86
29.
Zurück zum Zitat Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993; 72: 23–5BCrossRef Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993; 72: 23–5BCrossRef
30.
Zurück zum Zitat Harrigan E, Miceli J, Anzizno A, et al. A randomized evaluation of the effects of six antipsychotic agents on the QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharm 2004; 24(1): 62–9CrossRef Harrigan E, Miceli J, Anzizno A, et al. A randomized evaluation of the effects of six antipsychotic agents on the QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharm 2004; 24(1): 62–9CrossRef
31.
Zurück zum Zitat Blair J, Scahill L, State M, et al. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 2005; 44(1): 73–9PubMedCrossRef Blair J, Scahill L, State M, et al. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 2005; 44(1): 73–9PubMedCrossRef
32.
Zurück zum Zitat Loebel A, Miceli J, Chappell P, et al. Electrocardiographic changes with ziprasidone [letter]. J Am Acad Child Adolesc Psychiatry 2006; 45(6): 636–7PubMedCrossRef Loebel A, Miceli J, Chappell P, et al. Electrocardiographic changes with ziprasidone [letter]. J Am Acad Child Adolesc Psychiatry 2006; 45(6): 636–7PubMedCrossRef
33.
Zurück zum Zitat Malone RP, Delaney MA, Cater JR, et al. Ziprasidone in adolescents with autism: an open pilot study. J Child Adolesc Psychopharm 2007; 17(6): 779–90CrossRef Malone RP, Delaney MA, Cater JR, et al. Ziprasidone in adolescents with autism: an open pilot study. J Child Adolesc Psychopharm 2007; 17(6): 779–90CrossRef
34.
Zurück zum Zitat McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002; 41(8): 921–7PubMedCrossRef McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002; 41(8): 921–7PubMedCrossRef
35.
Zurück zum Zitat Kane J, Carson W, Saha A, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763–71PubMedCrossRef Kane J, Carson W, Saha A, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763–71PubMedCrossRef
36.
Zurück zum Zitat Potkin S, Saha A, Kujawa M, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681–90PubMedCrossRef Potkin S, Saha A, Kujawa M, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681–90PubMedCrossRef
37.
Zurück zum Zitat Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behaviors in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004; 14(3): 455–63PubMedCrossRef Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behaviors in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004; 14(3): 455–63PubMedCrossRef
38.
Zurück zum Zitat Valicenti-McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 2006; 16(5): 549–60PubMedCrossRef Valicenti-McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 2006; 16(5): 549–60PubMedCrossRef
39.
Zurück zum Zitat Owen R, Findling RL, Carlson G, et al. Efficacy and safety of aripiprazole in the treatment of serious behavioral problems associated with autistic disorder in children and adolescents (6–17 years old): results from a double-blind, randomized, placebo-controlled trial (Study CN 138-178). Poster presentation at the 55th annual meeting of the American Academy of Child and Adolescent Psychiatry 2008 Oct 28–Nov 2; Chicago (IL) Owen R, Findling RL, Carlson G, et al. Efficacy and safety of aripiprazole in the treatment of serious behavioral problems associated with autistic disorder in children and adolescents (6–17 years old): results from a double-blind, randomized, placebo-controlled trial (Study CN 138-178). Poster presentation at the 55th annual meeting of the American Academy of Child and Adolescent Psychiatry 2008 Oct 28–Nov 2; Chicago (IL)
40.
Zurück zum Zitat Owen R, Marcus R, Aman MG, et al. Efficacy and safety of aripiprazole in the treatment of serious behavioral problems associated with autistic disorder in children and adolescents (6–17 years old): results from a fixed-dose, double-blind, randomized, placebo-controlled trial (Study CN 138-179). Poster presentation at the 55th annual meeting of the American Academy of Child and Adolescent Psychiatry 2008 Oct 28–Nov 2; Chicago (IL) Owen R, Marcus R, Aman MG, et al. Efficacy and safety of aripiprazole in the treatment of serious behavioral problems associated with autistic disorder in children and adolescents (6–17 years old): results from a fixed-dose, double-blind, randomized, placebo-controlled trial (Study CN 138-179). Poster presentation at the 55th annual meeting of the American Academy of Child and Adolescent Psychiatry 2008 Oct 28–Nov 2; Chicago (IL)
41.
Zurück zum Zitat Zuddas A, Ledda MG, Fratta A, et al. Clinical effects of clozapine on autistic disorder [letter]. Am J Psychiatry 1996; 153: 738PubMed Zuddas A, Ledda MG, Fratta A, et al. Clinical effects of clozapine on autistic disorder [letter]. Am J Psychiatry 1996; 153: 738PubMed
42.
Zurück zum Zitat Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 2004; 14(2): 287–94PubMedCrossRef Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 2004; 14(2): 287–94PubMedCrossRef
43.
Zurück zum Zitat Martin A, Koenig K, Scahill L, et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999; 9(2): 99–107PubMedCrossRef Martin A, Koenig K, Scahill L, et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999; 9(2): 99–107PubMedCrossRef
44.
Zurück zum Zitat Corson AH, Barkenbus JE, Posey DJ, et al. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 2004; 65(11): 1531–6PubMedCrossRef Corson AH, Barkenbus JE, Posey DJ, et al. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 2004; 65(11): 1531–6PubMedCrossRef
45.
Zurück zum Zitat Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006; 16: 575–87PubMedCrossRef Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006; 16: 575–87PubMedCrossRef
46.
Zurück zum Zitat Laita P, Cifuentes A, Doll A, et al. Antipsyhotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol 2007; 17: 487–501PubMedCrossRef Laita P, Cifuentes A, Doll A, et al. Antipsyhotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol 2007; 17: 487–501PubMedCrossRef
47.
Zurück zum Zitat Hellings JA, Zarcone JR, Crandall K, et al. Weight gained in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 2001; 11: 229–38PubMedCrossRef Hellings JA, Zarcone JR, Crandall K, et al. Weight gained in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 2001; 11: 229–38PubMedCrossRef
48.
Zurück zum Zitat Masi G, Cosenza A, Mucci M, et al. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Pyschiatry 2003; 64: 1039–47CrossRef Masi G, Cosenza A, Mucci M, et al. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Pyschiatry 2003; 64: 1039–47CrossRef
49.
Zurück zum Zitat Hellings JA, Zarcone JR, Reese RM, et al. Crossover study of risperidone in children, adolescents and adults with mental retardation. J Autism Dev Disord 2006; 36: 401–11PubMedCrossRef Hellings JA, Zarcone JR, Reese RM, et al. Crossover study of risperidone in children, adolescents and adults with mental retardation. J Autism Dev Disord 2006; 36: 401–11PubMedCrossRef
50.
Zurück zum Zitat Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 2004; 39: 486–7 Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 2004; 39: 486–7
51.
Zurück zum Zitat Malone RP. Stereotypies and neuroleptic-related dyskinesias in children with autism. in: richardson ma, haughland g, editors. use of Neuroleptics in Children. Washington, DC: American Psychiatric Press, 1995: 121–36 Malone RP. Stereotypies and neuroleptic-related dyskinesias in children with autism. in: richardson ma, haughland g, editors. use of Neuroleptics in Children. Washington, DC: American Psychiatric Press, 1995: 121–36
52.
Zurück zum Zitat Malone RP, Sheikh R, Zito JM. Novel antipsychotic medications in the treatment of children and adolescents. Psychiatr Serv 1999; 50(2): 171–4PubMed Malone RP, Sheikh R, Zito JM. Novel antipsychotic medications in the treatment of children and adolescents. Psychiatr Serv 1999; 50(2): 171–4PubMed
53.
Zurück zum Zitat Lee PE, Sykora K, Sudeep SS, et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc 2005; 53: 1374–9PubMedCrossRef Lee PE, Sykora K, Sudeep SS, et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc 2005; 53: 1374–9PubMedCrossRef
54.
Zurück zum Zitat Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation anti-psychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161(3): 414–25PubMedCrossRef Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation anti-psychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161(3): 414–25PubMedCrossRef
55.
Zurück zum Zitat Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005; 50(11): 703–14PubMed Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005; 50(11): 703–14PubMed
56.
Zurück zum Zitat Connor DF, Fletcher KE, Wood JS. Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 2001; 62(12): 967–74PubMedCrossRef Connor DF, Fletcher KE, Wood JS. Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 2001; 62(12): 967–74PubMedCrossRef
57.
Zurück zum Zitat Brixner DL, Said Q, Corey-Lisle PK, et al. Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother 2006; 40: 626–32PubMedCrossRef Brixner DL, Said Q, Corey-Lisle PK, et al. Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother 2006; 40: 626–32PubMedCrossRef
58.
Zurück zum Zitat Hellings JA, Zarcone JR, Valdovinos MG, et al. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005; 15(6): 885–92PubMedCrossRef Hellings JA, Zarcone JR, Valdovinos MG, et al. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005; 15(6): 885–92PubMedCrossRef
59.
Zurück zum Zitat American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; and the North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. J Clin Psychiatry 2004; 65(2): 267–72CrossRef American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; and the North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. J Clin Psychiatry 2004; 65(2): 267–72CrossRef
Metadaten
Titel
The Role of Antipsychotics in the Management of Behavioural Symptoms in Children and Adolescents with Autism
verfasst von
Prof. Richard P. Malone
Ayesha Waheed
Publikationsdatum
01.03.2009
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 5/2009
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200969050-00003

Weitere Artikel der Ausgabe 5/2009

Drugs 5/2009 Zur Ausgabe

Adis Drug Profile

Eltrombopag

Adis Drug Evaluation

Tocilizumab

Adis Drug Evaluation

Buprenorphine/Naloxone